Business Context and Reporting Period
This Form 8-K reports the consummation of the Initial Public Offering (IPO) by Panacea Acquisition Corp. (a Special Purpose Acquisition Company), not Nuvation Bio Inc. The report date is July 6, 2020. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
- Gross Proceeds from IPO: $143,750,000 from the sale of 14,375,000 Units at $10.00 per Unit.
- Gross Proceeds from Private Placement: $4,875,000 from the sale of 487,500 Private Placement Units to the Sponsor and co-investors at $10.00 per Unit.
- Total Funds in Trust: $143,750,000 placed in a U.S.-based trust account at J.P. Morgan Chase Bank, N.A.
- Warrant Exercise Price: $11.50 per share.
- Revenue/Profit/Cash Flow: The filing text does not provide operating revenue, net profit, or operating cash flow figures as this is a pre-operational SPAC IPO filing.
- Debt: The filing text does not explicitly state outstanding debt levels, though an audited balance sheet is referenced as Exhibit 99.1.
Material Changes
The primary material change is the transition from a private entity to a publicly traded company on the New York Stock Exchange (NYSE) under the symbols PANA (Class A Common Stock), PANA.U (Units), and PANA WS (Warrants). The Company has raised significant capital which is now restricted in a trust account pending a future business combination.
Outlook, Risks, and Management Commentary
- Capital Structure: Each Unit consists of one share of Class A common stock and one-third of one redeemable warrant.
- Underwriter Option: The underwriters exercised their option in full to purchase an additional 1,875,000 Units.
- Private Placement: Concurrent with the IPO, the Sponsor (EcoR1 Panacea Holdings, LLC) and PA Co-Investment LLC purchased Private Placement Units to support the trust account.
- Future Operations: As a SPAC, the Company's primary objective is to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses.
Investor Verification Checklist
- Verify the identity of the registrant: This filing is for Panacea Acquisition Corp., not Nuvation Bio Inc.
- Confirm the trust account balance of $143,750,000 via the audited balance sheet (Exhibit 99.1).
- Review the terms of the redeemable warrants, specifically the $11.50 exercise price and redemption conditions.
- Check for any subsequent filings regarding the selection of a target company for business combination.